open access

Vol 8, No 5 (2012)
Review paper
Published online: 2012-11-27
Get Citation

Quality of life of patients with advanced breast cancer treated with lapatinib and capecitabine

Piotr Potemski
Onkol. Prak. Klin 2012;8(5):204-208.

open access

Vol 8, No 5 (2012)
REVIEW ARTICLES
Published online: 2012-11-27

Abstract

A randomized, open-label, phase III trial compared lapatinib and capecitabine with capecitabine monotherapyin advanced, HER2-positive breast cancer. The primary end-point was time to progression anda significant difference in favour of combination therapy has been found (median 8.4 v. 4.4 months,HR = 0.49, 95% CI 0.34–0.71; p < 0.001). However, no advantage in an overall survival has been observed.As a goal of palliative therapy is the prolongation of overall survival or the improvement of quality of life,two separate quality of life analyses of patients treated in this trial have been published. The first oneused conventional method based on FACT-B and EQ-5D questionarries — quality of life was preserved inpatients treated with lapatinib and capecitabine. The quality-adjusted time without symptoms of disease ortoxicity of treatment (Q-TWIST) method showed that combined therapy resulted in statistically significantprolongation of Q-TWIST in a comparison with capecitabine alone.

Abstract

A randomized, open-label, phase III trial compared lapatinib and capecitabine with capecitabine monotherapyin advanced, HER2-positive breast cancer. The primary end-point was time to progression anda significant difference in favour of combination therapy has been found (median 8.4 v. 4.4 months,HR = 0.49, 95% CI 0.34–0.71; p < 0.001). However, no advantage in an overall survival has been observed.As a goal of palliative therapy is the prolongation of overall survival or the improvement of quality of life,two separate quality of life analyses of patients treated in this trial have been published. The first oneused conventional method based on FACT-B and EQ-5D questionarries — quality of life was preserved inpatients treated with lapatinib and capecitabine. The quality-adjusted time without symptoms of disease ortoxicity of treatment (Q-TWIST) method showed that combined therapy resulted in statistically significantprolongation of Q-TWIST in a comparison with capecitabine alone.
Get Citation

Keywords

breast cancer; lapatinib; capecitabine; quality of life

About this article
Title

Quality of life of patients with advanced breast cancer treated with lapatinib and capecitabine

Journal

Oncology in Clinical Practice

Issue

Vol 8, No 5 (2012)

Article type

Review paper

Pages

204-208

Published online

2012-11-27

Bibliographic record

Onkol. Prak. Klin 2012;8(5):204-208.

Keywords

breast cancer
lapatinib
capecitabine
quality of life

Authors

Piotr Potemski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl